CAS Number84057-84-1
SynonymsLamictal; Lamotrigin; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; EINECS 281-901-8; 6-(2,3-Dichlorophenyl)-3-imino-3,4-dihydro-1,2,4-triazin-5-amine; Crisomet; Lamictal CD; HYDROXYMETHYL PROGESTERONE; 6-O-TRITYL-1,2,3,4-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSE; LAMOTRIGENE; LAMOTRIGINE API; MFCD00865333; LAMOTRIGINE / 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE-3,5-DIAMINE; Lamictal XR; Lamotrigina; Labileno; Lamotriginum; Lamotrigine
Molecular FormulaC9H7Cl2N5
Molecular Weight256.09
Purity99%
Density1.6±0.1 g/cm3
Boiling Point503.1±60.0 °C at 760 mmHg
Melting Point177-181°C
AppearanceWhite crystal
EINECS281-901-8
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 84057-84-1 |
| Catalog No. | 2A-9011119 |
| Chinese Name | 拉莫三嗪 |
| Synonyms | Lamictal; Lamotrigin; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; EINECS 281-901-8; 6-(2,3-Dichlorophenyl)-3-imino-3,4-dihydro-1,2,4-triazin-5-amine; Crisomet; Lamictal CD; HYDROXYMETHYL PROGESTERONE; 6-O-TRITYL-1,2,3,4-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSE; LAMOTRIGENE; LAMOTRIGINE API; MFCD00865333; LAMOTRIGINE / 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE-3,5-DIAMINE; Lamictal XR; Lamotrigina; Labileno; Lamotriginum; Lamotrigine |
| Molecular Formula | C9H7Cl2N5 |
| Molecular Weight | 256.09 |
| Purity | 99 |
| Density | 1.6±0.1 g/cm3 |
| Boiling Point | 503.1±60.0 °C at 760 mmHg |
| Melting Point | 177-181°C |
| Appearance | White crystal |
| Water Solubility | DMSO: 20 mg/mL at 60 °C, soluble |
| Storage Condition | 2-8°C |
| Packaging | III |
| Application | Lamotrigine (BW430C) can inhibit 5-HT and sodium ion channels and can act on convulsions. |
| EINECS | 281-901-8 |
| HTC | 2933699090 |
| PubChem ID | 329823366 |
| MDL Number | MFCD00865333 |
| SMILES | Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl |
| InChI | 1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16) |
| InChI Key | PYZRQGJRPPTADH-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | 6.1(b) |
| MSDS | msds/11119_1_84057_84_1.pdf |
| Bioactivity | Lamotrigine(BW430C) is a novel anticonvulsant drug for inhibition of 5-HT and sodium channelTarget: Sodium ChannelLamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly glutamate and aspartate [1]. In rat cerebral cortex tissue incubated with veratrine 10 mg/L, lamotrigine is twice as potent in inhibiting the release of glutamate and aspartate (ED 50 = 5.38 mg/L for each) than the release of GABA (ED50 = 11.2 mg/L), and is much less potent in inhibiting acetylcholine release (ED50 = 25.6 mg/L) when cortical slices is exposed to veratrine 75 mg/L. Basal glutamate release is unaffected [2]. Lamotrigine inhibits high-frequency sustained repetitive firing of sodium-dependent action potentials, indicating a direct effect on voltage-activated sodium channels [3]. Lamotrigine (Lamictal), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder. lamotrigine significantly delayed time to intervention for a depressive episode and showed limited efficacy in delaying time to intervention for a manic/hypomanic episode, compared with placebo. Lamotrigine is generally well tolerated [4]. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease References [1]. Goa, K.L., S.R. Ross, and P. Chrisp, Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs, 1993. 46(1): p. 152-76. [2]. Leach, M.J., C.M. Marden, and A.A. Miller, Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 1986. 27(5): p. 490-7. [3]. Cheung, H., D. Kamp, and E. Harris, An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res, 1992. 13(2): p. 107-12. [4]. Goldsmith, D.R., et al., Lamotrigine: a review of its use in bipolar disorder. Drugs, 2003. 63(19): p. 2029-50. Chemical & Physical Properties Density 1.6±0.1 g/cm3 Boiling Point 503.1±60.0 °C at 760 mmHg Melting Point 177-181°C Molecular Formula C9H7Cl2N5 Molecular Weight 256.091 Flash Point 258.1±32.9 °C Exact Mass 255.007858 PSA 90.71000 LogP -0.19 Vapour Pressure 0.0±1.3 mmHg at 25°C Index of Refraction 1.706 InChIKey PYZRQGJRPPTADH-UHFFFAOYSA-N SMILES Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1 Storage condition 2-8°C Water Solubility DMSO: 20 mg/mL at 60 °C, soluble |
| Use of | Properties Articles74 Name lamotrigine Synonym More Synonyms lamotrigine Biological Activity Related Catalog Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel Research Areas >> Neurological Disease References [1]. Goa, K.L., S.R. Ross, and P. Chrisp, Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs, 1993. 46(1): p. 152-76. [2]. Leach, M.J., C.M. Marden, and A.A. Miller, Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 1986. 27(5): p. 490-7. [3]. Cheung, H., D. Kamp, and E. Harris, An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res, 1992. 13(2): p. 107-12. [4]. Goldsmith, D.R., et al., Lamotrigine: a review of its use in bipolar disorder. Drugs, 2003. 63(19): p. 2029-50. Chemical & Physical Properties Exact Mass 255.007858 PSA 90.71000 LogP -0.19 Index of Refraction 1.706 InChIKey PYZRQGJRPPTADH-UHFFFAOYSA-N |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 United Nations shipping name European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Lamotrigine) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (Lamotrigine) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Lamotrigine) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available The above information is believed to be correct, but is not all-inclusive and should be used as a guide only. The information in this document is based on our current knowledge and is Correct safety instructions apply to this product. This information does not represent a warranty as to the properties of this product. See reverse side of invoice or packing slip. |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Ketoprofen | 22071-15-4 | 2A-9011100 |
| LaBetalol | 36894-69-6 | 2A-9011109 |
| LaBetalol hydrochloride | 32780-64-6 | 2A-9011110 |
| Lacidipine | 103890-78-4 | 2A-9011112 |
| Lamivudine | 134678-17-4 | 2A-9011118 |
| Lansoprazole | 103577-45-3 | 2A-9011124 |
| Lansoprazole Sulphide compound | 103577-40-8 | 2A-9011125 |
| Letrozole | 112809-51-5 | 2A-9011156 |
| Levodopa | 59-92-7 | 2A-9011171 |
| Levofloxacin | 100986-85-4 | 2A-9011173 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS